Diamyd Medical's NTDDS technology effective against diabetes pain
Diamyd Medical reports that its Nerve Targeting Drug Delivery System (NTDDS)
expressing enkephalin, is effective in preclinical models of diabetes pain.
Dr. David Fink, published in the scientific journal “Journal of Neuroscience”
that Diamyd Medical's proprietary NTDDS platform, expressing enkephalin,
effectively relieves pain due to diabetes in animals. The NTDDS platform allows
focal delivery of the human enkephalin gene directly to nerves experiencing
pain.
”These new data indicate that not only is the NTDDS platform with enkephalin
effective at reducing pain, it reverses the root cause of diabetes related pain.
This means that the approach is not just pain relief, but local pain
prevention”, says Darren Wolfe, President of Diamyd Inc.
Elisabeth Lindner, President and CEO of Diamyd Medical, states “We have
positioned Diamyd Medical as a diabetes company. These exciting results give us
the opportunity to expand our product portfolio to include a third diabetes
related product, NP2”.
Diamyd's product NP2 (NTDDS expressing enkephalin), is currently in Phase I
clinical safety studies. Dr. Fink, Professor and chair of the Department of
Neurology at the University of Michigan, is the Principal Investigator for this
study.
Diamyd Medical's diabetes product portfolio includes NP2, Diamyd® vaccine for
type 1 diabetes and Diamyd® vaccine for LADA.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
elisabeth.lindner@diamyd.com
Phone: +46-8-661 0026
Darren Wolfe, President Diamyd Inc., darren.wolfe@diamyd.com
Phone +1-412-770-1310
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ),
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-post: info@diamyd.com. VATno: SE556530-142001.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials are ongoing in both the US and Europe.
Furthermore, the company has initiated clinical studies within chronic pain,
using its Nerve Targeting Drug Delivery System (NTDDS). The company has also
out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
